Boston Scientific D&A increased by 6.7% to $365.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 4.9%, from $348.00M to $365.00M. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 5.8% CAGR.
Higher levels typically reflect significant historical capital expenditures or acquisitions that are now being expensed over time.
This metric represents the non-cash accounting charges used to allocate the cost of tangible assets and intangible asset...
Capital-intensive hardware manufacturers generally show higher D&A relative to revenue than pure-play software companies.
cf_depreciation_and_amortization| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $263.00M | $272.00M | $290.00M | $274.00M | $284.00M | $284.00M | $294.00M | $285.00M | $298.00M | $300.00M | $313.00M | $304.00M | $311.00M | $306.00M | $348.00M | $325.00M | $336.00M | $342.00M | $365.00M |
| QoQ Change | — | +3.4% | +6.6% | -5.5% | +3.6% | +0.0% | +3.5% | -3.1% | +4.6% | +0.7% | +4.3% | -2.9% | +2.3% | -1.6% | +13.7% | -6.6% | +3.4% | +1.8% | +6.7% |
| YoY Change | — | — | — | — | +8.0% | +4.4% | +1.4% | +4.0% | +4.9% | +5.6% | +6.5% | +6.7% | +4.4% | +2.0% | +11.2% | +6.9% | +8.0% | +11.8% | +4.9% |